 Glomerulonephritis, Membranoproliferative
"Glomerulonephritis, Membranoproliferative" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Chronic glomerulonephritis characterized histologically by proliferation of MESANGIAL CELLS, increase in the MESANGIAL EXTRACELLULAR MATRIX, and a thickening of the glomerular capillary walls. This may appear as a primary disorder or secondary to other diseases including infections and autoimmune disease SYSTEMIC LUPUS ERYTHEMATOSUS. Various subtypes are classified by their abnormal ultrastructures and immune deposits. Hypocomplementemia is a characteristic feature of all types of MPGN.
| Descriptor ID |
D015432
|
| MeSH Number(s) |
C12.777.419.570.363.615 C13.351.968.419.570.363.615 C20.425
|
| Concept/Terms |
Glomerulonephritis, Membranoproliferative- Glomerulonephritis, Membranoproliferative
- Glomerulonephritides, Membranoproliferative
- Membranoproliferative Glomerulonephritides
- Glomerulonephritis, Mesangiocapillary
- Glomerulonephritides, Mesangiocapillary
- Mesangiocapillary Glomerulonephritides
- MPGN
- Membranoproliferative Glomerulonephritis
- Mesangiocapillary Glomerulonephritis
- Glomerulonephritis, Hypocomplementemic
- Glomerulonephritides, Hypocomplementemic
- Hypocomplementemic Glomerulonephritides
- Hypocomplementemic Glomerulonephritis
Membranoproliferative Glomerulonephritis, Type I- Membranoproliferative Glomerulonephritis, Type I
- Subendothelial Membranoproliferative Glomerulonephritis
- Membranoproliferative Glomerulonephritis, Subendothelial
- Mesangiocapillary Glomerulonephritis, Type I
|
Below are MeSH descriptors whose meaning is more general than "Glomerulonephritis, Membranoproliferative".
Below are MeSH descriptors whose meaning is more specific than "Glomerulonephritis, Membranoproliferative".
This graph shows the total number of publications written about "Glomerulonephritis, Membranoproliferative" by people in this website by year, and whether "Glomerulonephritis, Membranoproliferative" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1997 | 1 | 0 | 1 | | 2004 | 1 | 1 | 2 | | 2007 | 1 | 0 | 1 | | 2008 | 0 | 1 | 1 | | 2012 | 0 | 1 | 1 | | 2015 | 1 | 0 | 1 | | 2018 | 0 | 1 | 1 | | 2020 | 0 | 1 | 1 | | 2021 | 1 | 0 | 1 | | 2022 | 3 | 0 | 3 | | 2023 | 1 | 0 | 1 | | 2025 | 1 | 0 | 1 |
To return to the timeline, click here.
Below are the most recent publications written about "Glomerulonephritis, Membranoproliferative" by people in Profiles.
-
Fakhouri F, Bomback AS, Ariceta G, Delmas Y, Dixon BP, Gale DP, Greenbaum LA, Han SH, Isbel N, Le Quintrec M, Licht C, Mastrangelo A, Mizuno M, Neves de Holanda MI, Pickering MC, Remuzzi G, Van De Kar N, Vivarelli M, Walker PD, Wallace D, Zecher D, Francois C, Deschatelets P, Li L, Wang Z, Abad-Franch L, Kinnman N, López-Lázaro L, Szamosi J, Nester CM. Trial of Pegcetacoplan in C3 Glomerulopathy and Immune-Complex MPGN. N Engl J Med. 2025 Dec 04; 393(22):2210-2220.
-
Antonucci L, Thurman JM, Vivarelli M. Complement inhibitors in pediatric kidney diseases: new therapeutic opportunities. Pediatr Nephrol. 2024 May; 39(5):1387-1404.
-
Nester C, Appel GB, Bomback AS, Bouman KP, Cook HT, Daina E, Dixon BP, Rice K, Najafian N, Hui J, Podos SD, Langman CB, Lightstone L, Parikh SV, Pickering MC, Sperati CJ, Trachtman H, Tumlin J, de Vries AP, Wetzels JFM, Remuzzi G. Clinical Outcomes of Patients with C3G or IC-MPGN Treated with the Factor D Inhibitor Danicopan: Final Results from Two Phase 2 Studies. Am J Nephrol. 2022; 53(10):687-700.
-
Podos SD, Trachtman H, Appel GB, Bomback AS, Dixon BP, Wetzels JFM, Cook HT, Parikh SV, Pickering MC, Tumlin J, Langman CB, Lightstone L, Sperati CJ, Daina E, Bouman KP, Rice K, Thanassi JA, Huang M, Nester C, Remuzzi G. Baseline Clinical Characteristics and Complement Biomarkers of Patients with C3 Glomerulopathy Enrolled in Two Phase 2 Studies Investigating the Factor D Inhibitor Danicopan. Am J Nephrol. 2022; 53(10):675-686.
-
Li A, Ambruso SL, Oto OA, Barry M, Edelstein CL. A case report of pre-eclampsia-like endothelial injury in the kidney of an 85-year-old man treated with ibrutinib. BMC Nephrol. 2022 07 23; 23(1):264.
-
Vivarelli M, van de Kar N, Labbadia R, Diomedi-Camassei F, Thurman JM. A clinical approach to children with C3 glomerulopathy. Pediatr Nephrol. 2022 03; 37(3):521-535.
-
Laskowski J, Renner B, Pickering MC, Serkova NJ, Smith-Jones PM, Clambey ET, Nemenoff RA, Thurman JM. Complement factor H-deficient mice develop spontaneous hepatic tumors. J Clin Invest. 2020 08 03; 130(8):4039-4054.
-
Goetz L, Laskowski J, Renner B, Pickering MC, Kulik L, Klawitter J, Stites E, Christians U, van der Vlag J, Ravichandran K, Holers VM, Thurman JM. Complement factor H protects mice from ischemic acute kidney injury but is not critical for controlling complement activation by glomerular IgM. Eur J Immunol. 2018 05; 48(5):791-802.
-
Rajasekaran A, Ngo TT, Abdelrahim M, Glass W, Podoll A, Verstovsek S, Abudayyeh A. Primary myelofibrosis associated glomerulopathy: significant improvement after therapy with ruxolitinib. BMC Nephrol. 2015 Aug 01; 16:121.
-
Thurman JM. Factor friction: protective and pathogenic roles for complement factors in immune complex glomerulonephritis. Kidney Int. 2012 Nov; 82(9):945-7.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|